Patient
SITE015-0129
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2026-02-02
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 4
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 217); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 214); relationship: NOT RELATED
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 133); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 12); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.